VIDEO: KSI-301 shows ‘great durability in all indications’
Click Here to Manage Email Alerts
An antibody biopolymer conjugate showed safety, efficacy and durability compared to aflibercept in various retinal conditions, according to research presented at the virtual American Academy of Ophthalmology annual meeting.
Arshad M. Khanani, MD, MA, managing partner and director of clinical research, Sierra Eye Associates, clinical associate professor of ophthalmology, University of Nevada, reviewed his findings from the long-term multiple-dose study of antibody biopolymer conjugates (ABCs) and discussed positive clinical results of KSI-301 in wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.
“If we are able to have the similar efficacy and safety in the pivotal trials, I think it's going to help physicians as well as patients, by decreasing the number of visits and number of injections that are required to maintain or improve vision in patients with wet AMD, DME and RVO. KSI-301 can address the top unmet need of having a durable agent with similar efficacy and safety as current agents to help patients decrease their visits to the clinic,” Khanani told Healio.
Collapse
Khanani, AM. One Year and Beyond: Long-Term Multiple-Dose Study of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate with Extended Durability, in wAMD, DME, and RVO. Presented at: American Academy of Ophthalmology annual meeting; Nov.13-15, 2020 (virtual meeting).
Read more about
Click Here to Manage Email Alerts